About this episode

This episode features discussions on the current and future roles of TROP2-directed therapies and established treatment paradigms for triple-negative breast cancer.

Featuring perspectives from Dr Adam M Brufsky and Dr Kevin Kalinsky, including the following topics: Introduction (0:00) Current and Future Role of TROP2-Directed Antibody-Drug Conjugates in Therapy for Triple-Negative Breast Cancer (TNBC) — Dr Brufsky (5:08) Established Treatment Paradigm for Localized and Metastatic TNBC — Dr Kalinsky (35:20) CME information and select publications

People in this episode

Host: Dr Neil Love

Guests: Dr Adam M Brufsky, Dr Kevin Kalinsky

Topics covered

• Triple-Negative Breast Cancer
• TROP2-Directed Antibody-Drug Conjugates
• Treatment Paradigm
• Localized TNBC
• Metastatic TNBC

Keywords

• breast cancer
• triple-negative
• TROP2
• antibody-drug conjugates
• oncology
• treatment
• CME

Mentioned in this episode

Books & works: Triple-Negative Breast Cancer

More episodes of Breast Cancer Update

• HER2-Positive Metastatic Breast Cancer — An Interview with Prof Dr Sibylle Loibl on First-Line and Maintenance Therapy · July 18, 2026 · 46 min
• Localized HR-Positive Breast Cancer — Year in Review Series on Relevant New Datasets and Advances · July 13, 2026 · 58 min
• For Oncology Nurses: Strategies to Safely and Effectively Implement Antibody-Drug Conjugates — Proceedings from the 2026 Annual ONS Congress · July 10, 2026 · 1h 29m
• Antibody-Drug Conjugates in the Management of Breast Cancer — Proceedings from a Session Held in Conjunction with the 2026 ASCO Annual Meeting · July 8, 2026 · 2h 0m
• HR-Positive Breast Cancer — Fifth Annual National General Medical Oncology Summit · June 29, 2026 · 1h 39m
• Metastatic Triple-Negative Breast Cancer — What Clinicians Want to Know · June 26, 2026 · 54 min

Explore listener stats, chart rankings, contacts and more on the Breast Cancer Update podcast page.